ABT hasn’t yet released a statement on its anti-NGF drug (#msg-43510907), but the fact that the FDA sees a class effect can’t be good for this program.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”